• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / Rheumatoid Arthritis News / Mechanisms of the Atheroprotective Effect of Methotrexate Studied

Mechanisms of the Atheroprotective Effect of Methotrexate Studied

January 6, 2009 By Arthritis Center

Coronary Artery with Atherosclerosis
Coronary Artery with Atherosclerosis

RA patients who use methotrexate have been shown to have lower cardiovascular mortality compared to non-users; however, the mechanism underlying this protection is unclear.  Here, Reiss et al (Arthritis Rheum 2008; 58(12): 3675) explore the atheroprotective effects of methotrexate in an experimental model of atherogenesis.

Methods

THP-1 monocytes/macrophages and human donor peripheral blood mononuclear cells (PBMCs) were cultured and exposed singly and in varying combinations to increasing concentrations of methotrexate, pro-atherogenic factors (IFNγ and the COX-2 inhibitor NS398), and the adenosine A2A receptor agonist CGS21680 and antagonist ZM241385.  Differences in mRNA and protein expression for the anti-atherogenic proteins cholesterol 27-hydroxylase (27-OHase) and ATP-binding cassette transporter A1 (ABCA1), key mediators of the reverse cholesterol transport process, and the formation of macrophage foam cells after incubation with acetylated LDL were compared for the different exposure groups.

Results

Exposure to methotrexate increased mRNA and protein expression for the anti-atherogenic reverse cholesterol transport mediator 27-OHase while the COX-2 inhibitor NS398 reduced 27-OHase mRNA levels.  The effect of NS398 on 27-OHase mRNA levels was blocked when co-incubated with methotrexate.  Similarly, methotrexate abrogated the reduction in 27-OHase levels induced by incubation with IFNγ.  The effect of methotrexate on enhancing 27-OHase increased with increasing concentration of methotrexate.  Similar findings were seen when human PBMCs were used.

Both NS398 and IFNγ reduced mRNA levels of the anti-atherogenic protein ABCA1.  Co-incubation with methotrexate abrogated these effects and was associated with higher ABCA1 levels than in controls, despite the presence of NS398 and IFNγ.  Adding the adenosine A2A receptor antagonist reduced the beneficial effect of methotrexate, suggesting that methotrexate exerts its beneficial effect through the adenosine A2A receptor.
THP-1 macrophages incubated with LDL transformed readily into foam cells when exposed to INFγ or the COX-2 inhibitor NS398.  Foam cell transformation was reduced when co-exposed to methotrexate.  Methotrexate was not effective at reducing foam cell transformation when the adenosine A2A receptor was blocked with ZM241385.

Conclusions

Methotrexate upregulated important anti-atherogenic proteins involved in the reverse cholesterol transport process and abrogated the detrimental effect of COX-2 inhibition and IFNγ on these proteins and macrophage foam cell transformation.

Editorial Comment

These are a very elegant set of experiments that help to explain why methotrexate, in contrast to other non-biologic DMARDs, appears to convey a cardiovascular mortality benefit in users.  It should be notes, however, that these results are from an in vitro experimental model of atherogenesis, and may function differently in vivo in the environment of an actual artery.  Regardless, these results suggesting cardioprotection provide additional justification for methotrexate as the cornerstone of therapy for inflammatory arthritis.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy